natgillin/translations-raw huggingface dataset:
8 mg orally
8 mg peroralno
8 mg orally once daily
8 mg peroralno jedanput na dan
8 mg Pegloticase Every 2 Weeks (N = 62)
Peglotikaza 8 mg svaka 2 tjedna (N = 62)
8 mg/24 h Transdermal patch
8 mg/24 h Transdermalni flaster
8 mg/k g
8 mg/ kg
8 mg/kg every
8 mg/kg svakih
8 mg/kg once daily
8 mg/kg jedanput na dan
8 mg/kg or
8 mg/kg ili
8 mg/m2 i.v. (0.5 h), days 7, 8, 14, 15; CP 500 mg/m2 i.v.(1 h) day 1; Ara-
8 mg/m2 i.v. (0,5 h), dani 7, 8, 14, 15; CP 500 mg/m2 i.v.(1 h) dan 1; Ara
8 ml (1000 U/ml-
8 ml (1 000 U/ml
8 ml of concentrate in a 10 ml clear borosilicate glass vial (type I) sealed by a flanged stopper with flip-off cap and inserted coated sealing disc.
8 ml koncentrata u prozirnoj bočici volumena 10 ml od borosilikatnog stakla (tip I), zatvorenoj čepom s rubnikom koji ima "flip-off" kapicu i uloženu obloženu zaštitnu pločicu.
8 ml of concentrate in a 10 ml clear borosilicate glass vial (type I), sealed by a flanged stopper with flip-off cap and inserted coated sealing disc.
8 ml koncentrata u prozirnoj bočici od 10 ml od borosilikatnog stakla (tip I) zatvorenoj čepom s rubnikom koji ima "flip-off" kapicu i uloženu obloženu zaštitnu pločicu.
8 mL round opaque low density polyethylene (LDPE) bottles with a LDPE dropper tip and white polypropylene screw cap (Drop-Tainer) containing 5 mL suspension.
Okrugle, neprozirne boce od polietilena niske gustoće volumena 8 ml, s nastavkom za kapanje od polietilena niske gustoće i bijelim polipropilenskim zatvaračem s navojem (Drop-Tainer) koje sadrže 5 ml suspenzije.
8 mL Type 1 glass vial with an elastomeric closure and an aluminium seal with a flip-off button containing 100 mg of siltuximab.
Bočica od stakla tipa I od 8 ml s elastomernim zatvaračem i aluminijskim “flip-off” zatvaračem koja sadrži 100 mg siltuksimaba.
8 mL type I glass vial with a butyl rubber stopper sealed with a flip-off seal.
Bočica od 8 ml od stakla tipa I, zatvorena butilnim gumenim čepom sa zaštitnim zatvaračem.
8 ml water for injections
8 ml vode za injekcije
8 ml/50 ml vial
8 ml/50 ml Staklena bočica
8 p-value displayed for descriptive purpose only
8 p-vrijednost navedena je samo u ilustrativne svrhe
8 pens + 96 injection needles + 96 cleansing swabs
8 brizgalica + 96 igala za injekciju + 96 tupfera za čišćenje
8 pens of 3 ml.
8 brizgalica od 3 ml.
8 pre-filled
8 napunjene
8 See section 4.4.
8 Vidjeti dio 4.4.
8 spray containers
8 jednodoznih spremnika
8 subjects with moderate renal impairment (CrCl 30 mL/min to < 50 mL/min), and 8 subjects with severe renal impairment (CrCl < 30 mL/min) as well as 8 subjects with ESRD on haemodialysis.
8 ispitanika s teškim oštećenjem bubrega (CrCl < 30 mL/min), kao i 8 ispitanika u završnom stadiju bubrežne bolesti.
8 tablets 12 tablets
4 tablete 8 tableta 12 tableta
8 tablets 12 tablets
8 tableta 12 tableta
8 tablets 12 tablets 2 tablets
8 tableta 12 tableta 2 tablete
8 the solvent vial with the blue Mix2Vial adapter attached.
8 zajedno s plavim adapterom uređaja Mix2Vial.
8 This adverse reaction was identified through post-marketing surveillance for tenofovir disoproxil fumarate but not observed in randomised controlled clinical studies or the expanded access program for tenofovir disoproxil fumarate.
8 Ova nuspojava je bila identificirana tijekom praćenja lijeka nakon stavljanja lijeka u promet tenofovirdizoproksilfumarata no nije zabilježena u randomiziranim kontroliranim kliničkim ispitivanjima ili programu proširenog pristupa tenofovirdizoproksilfumarata.
8 to less than 11
od 8 do manje od 11
8 transdermal patches
8 transdermalnih flastera
8 vials (multipack)
8 bočica (višestruko pakiranje)
8 vials of powder
8 bočice s praškom
8 week, acute endpoint
8 tjedana, akutn ishod
8 week, acute endpoint
8 tjedana, akutni ishod
8 weeks (n = 210)
8 tjedana (n = 210)
8 weeks (n = 213)
8 tjedana (n = 213)
8 weeks (n = 216)
8 tjedana (n = 216)
8 weeks after opening the bottle.
8 tjedana nakon otvaranja bočice.
8 weeks of therapy.
78% nakon 8 tjedana terapije.
8 weeks of treatment, further Tarceva treatment should be re-assessed (see section 5.1).
U bolesnika u kojih se u prvih 4 do 8 tjedana liječenja ne pojavi osip, potrebno je razmotriti potrebu daljnjeg liječenja lijekom Tarceva (vidjeti dio 5.1).
8 WITHDRAWAL PERIOD
8 KARENCIJA
8 x 1 tablets (unit
1 tableta
8 x 1 tablets (unit
8 x 1 tableta (s jediničnim dozama)
8 x 1 tablets (unit dose)
8 x 1 tableta (jedinična doza)
8 x 10 ml intramammary syringes 24 x 10 ml intramammary syringes 120 x 10 ml intramammary syringes
8 intramamarnih štrcaljki od 10 ml 24 intramamarne štrcaljke od 10 ml 120 intramamarnih štrcaljki od 10 ml
8% (-1 to 17%)
8% (-1 do 17%)
8, 24, 36, 48, and
8., 24., 36., 48. i
8, 24, 36, 48, and
8., 24., 36., 48. i 60. satu
8,000 IU/0.8 ml
8000 IU/0,8 ml
8,000 U tenecteplase per vial
8000 U tenekteplaze po bočici
8,281 patients with an acute symptomatic DVT or PE
8281 bolesnik s akutnom simptomatskim DVT-om ili plućnom embolijom
8.0 HR 0.60; p=0.0062
HR 0,60; p= 0,0062
8.0 mm, round, normal convex, white film-coated tablets debossed “OZ” over “5” on one side and “G” on the other side.
Okrugle, konveksne, bijele filmom obložene tablete veličine 8,0 mm, na kojima je s jedne strane utisnuta oznaka „OZ” iznad „5”, a s druge oznaka „G”.
8.0% vs 1.3%
8,0% vs 1,3
8.01
(n=195)
8.09
(n=197)
8.1 (6/74b)
Ciroza
8.1 months
8,1 mjeseci
8.1 to 9.9
8,1 do 9,9
8.2% (1.7; 14.7)d
8,2% (1,7; 14,7)d
8.3 (8.05; 9.43) p-value* < 0.0001
p-vrijednost* < 0,0001 omjer hazarda
8.3 months for patients treated with pemetrexed (Intent To Treat population n = 283) and 7.9 months for patients treated with docetaxel (ITT n = 288).
Analiza primarne djelotvornosti temeljila se na ITT populaciji.
8.3 months for patients treated with pemetrexed (Intent To Treat population n = 283) and 7.9 months for patients treated with docetaxel (ITT n = 288).
Intent-To-Treat [ITT], N = 283), a u bolesnika liječenih docetakselom 7,9 mjeseci (ITT populacija, N = 288).
8.3 months for patients treated with pemetrexed (Intent To Treat population n= 283) and 7.9 months for patients treated with docetaxel (ITT n= 288).
Intent-To-Treat [ITT], N=283), a u bolesnika liječenih docetakselom 7,9 mjeseci (ITT populacija, n = 288).
8.3 months for patients treated with pemetrexed (Intent To Treat population n=283) and 7.9 months for patients treated with docetaxel (ITT n=288).
Intent-To-Treat [ITT], n=283), a u bolesnika liječenih docetakselom 7,9 mjeseci (ITT populacija, n = 288).
8.3 ± 6.26
± SDa
8.4 micrograms
8,4 mikrograma
8.4% p=0.010 (2.0, 14.8)
8,4% p=0,010 (2,0; 14,8)
8.5
Ikatibant
8.5 l
8,5 L
8.5 ml/m2/day (9.4 g/m2/day) in patients with a body surface area (BSA) < 1.3 m2
8,5 ml/m2/dan (9,4 g/m2/dan) za bolesnike s površinom tijela < 1,3 m2
8.6
Ishod
8.7 μg/day, mean 25.7 μg/day – study 201) or with IT morphine (study 202) alone.
25,7 μg/dan - ispitivanje 201) ili intratekalnog morfina (ispitivanje 202).
8.8 micrograms (2.4 million IU)/0.2 mL
8,8 mikrograma (2,4 milijuna IU)/0,2 ml
8.8 micrograms tiw
8,8 mikrograma tri puta tjedno
8.9 m vs 6.1 m
8,9 m vs 6,1 m
80 - 100 (pre- and post- operative)
80 – 100 (prije i poslije operacije)
80 - 100 (pre- and postoperative)
80 - 100 (prije i nakon kirurškog
80 - 100 (pre- and postoperative)
80 - 100 (prije i nakon kirurškog zahvata)
80 ART-experienced HIV-1 infected paediatric patients aged from 6 to 17 years and weighing at least 20 kg who received PREZISTA tablets with low dose ritonavir twice daily in combination with other antiretroviral agents.
80 pedijatrijskih bolesnika u dobi od 6 do 17 godina i težine najmanje 20 kg, prethodno liječenih ART-om, a inficirani su virusom HIV-1 te su primali tablete lijeka PREZISTA s niskom dozom ritonavira dva puta na dan u kombinaciji s drugim antiretrovirusnim lijekovima.
80 mg docetaxel in 2 ml polysorbate 80 (40 mg/ml) Fill: 94.4 mg/2.36 ml
80 mg docetaksela u 2 ml polisorbata 80 (40 mg/ml) Punjenje: 94,4 mg/2,36 ml
80 mg Q2W
80 mg svaka
80 mg Q4W
80 mg svaka
80 mg QD
80 mg jednom dnevno
80 mg tablets are white, oval, biconvex with logo T1 on one side
Telmisartan Actavis 80 mg tablete su bijele, ovalne, bikonveksne s oznakom T1 na jednoj strani.
80 mg/12.5 mg tablets: White to almost white or pinkish white on one side and pink marbled on the opposite side of two-layer biconvex oval tablet, tablet dimensions 18 mm x 9 mm.
80 mg/12,5 mg tablete: dvoslojna, bikonveksna, ovalna tableta, bijela do gotovo bijela ili ružičasto- bijela na jednoj strani te ružičasto mramorirana na suprotnoj strani, veličine 18 mm x 9 mm.
80 mg/25 mg tablets: White to yellowish white on one side and yellow marbled on the opposite side of two-layer biconvex oval tablet, tablet dimensions 18 mm x 9 mm.
80 mg/25 mg tablete: dvoslojna, bikonveksna, ovalna tableta, bijela do žućkasto-bijela na jednoj strani te žuto mramorirana na suprotnoj strani, veličine 18 mm x 9 mm.
80 mg/m2(n=353)b
80 mg/m22(n=353)b
80 MHz to 800 MHz
80 MHz do 800 MHz
80 micrograms
80 mikrograma
80 pipettes
80 pipeta
80 – 100 (pre- and postoperative)
80 – 100 (prije i poslije operacije)
80% (8/10) of sphincter of Oddi spasm events presented within the first week of treatment.
80% (8/10) događaja spazma Oddijevog sfinktera javilo se unutar prvog tjedna liječenja.
80% [64,89]
2559 kontrola
80-100 (pre- and post-operative)
80-100 (prije i poslije kirurškog zahvata)
80-100 (pre- and postoperative)
80-100 (pre- i postoperacijski)
80/480 mg, 6 doses at 0,
80/480 mg, 6 doza u 0.,
800 (20 cartridges x 40) tablets
800 (20 ulošci x 40) tableta
800 536389 (altre domande)
800 536389 (altre domande e chiamate dall'estero)
800 Dwight Way Berkeley
Bayer HealthCare LLC 800 Dwight Way
800 Dwight Way,
Bayer HealthCare LLC 800 Dwight Way
800 mg carbamazepine or 400 mg of zonisamide.
800 mg karbamazepina ili 400 mg zonisamida.
800 mg pazopanib once daily is the recommended dose in patients with mild abnormalities in serum liver tests (defined as either normal bilirubin and any degree of alanine aminotransferase (ALT) elevation or as an elevation of bilirubin (> 35 % direct) up to 1.5 x upper limit of normal (ULN) regardless of the ALT value).
Preporučena doza pazopaniba je 800 mg jednom dnevno, u bolesnika s blagim poremećajima serumskih jetrenih testova (definirani kao ili normalni bilirubin i bilo koji stupanj povišenja alanin aminotransferaze (ALT) ili kao povišenje bilirubina (>35 % direktnog) do 1,5 x od gornje granice normale (GGN) neovisno o vrijednostima ALT-a).
800 mg pazopanib once daily is the recommended dose in patients with mild abnormalities in serum liver tests (either normal bilirubin and any degree of ALT elevation or as an elevation of bilirubin up to 1.5 x ULN regardless of the ALT value).
Preporučena doza pazopaniba je 800 mg jednom dnevno u bolesnika s blagim poremećajem serumskih jetrenih testova (definirani kao ili normalni bilirubin i bilo koji stupanj porasta vrijednosti alanin aminotransferaze (ALT) ili kao povišenje bilirubina do 1,5 x od gornje granice normale (GGN) neovisno o vrijednostima ALT-a).
800 mg three times daily
800 mg tri puta na dan
800 mg three times daily)
4 mg + Victrelis 800 mg triput na
800 mg three times daily)
Victrelis 800 mg triput na dan)
800 mg TID with a reference dose of 150 mg
QD i indinavira od 800 mg TID s
800 mg twice daily
800 mg dva puta na dan
800 mg/ 50 mL
800 mg/50 ml
800 mg/160 mg BID
dozi od 400 mg QID)
800 mg/day, respectively, and 1.2 times the daily exposure in children (based on AUC) at 340 mg/m2/day.
800 mg/dan te 1,2 puta dnevne izloženosti u djece (temeljeno na AUC) kod 340 mg/m2/dan.
800 MHz to 2,5 GHz
800 MHz do 2,5 GHz
800 MHz to 2,7 GHz
800 MHz do 2,7 GHz
800 MHz to 2.5 GHz
800 MHz do 2.5 GHz
800 micrograms fentanyl (as citrate)
800 mikrograma fentanila (u obliku fentanilcitrata)
800 micrograms.
400 mikrograma,
800 micrograms.
800 mikrograma.
800 milligram PREZISTA (2 tablets containing 400 milligram of PREZISTA or 1 tablet containing 800 milligram of PREZISTA) together with 100 milligram ritonavir once daily.
800 miligrama lijeka PREZISTA (2 tablete koje sadrže 400 miligrama lijeka PREZISTA ili 1 tableta koja sadrži 800 miligrama lijeka PREZISTA) zajedno sa 100 miligrama ritonavira jedanput na dan.
800 milligram PREZISTA together with 150 milligram cobicistat or100 milligram ritonavir once daily.
800 miligrama lijeka PREZISTA zajedno sa 150 miligrama kobicistata ili 100 miligrama ritonavira jedanput na dan.
800 ml polyethylene or multilayer plastic bags of solvent.
800 ml polietilen ili višeslojne plastične vrećice otapala.
800 μg/kg
μg/kg 800
800 – 1,200 IU
800-1200 IU
800/160 mg twice daily
dvaput na dan
800/400/100 mg twice daily.
800/400/100 mg dva puta na dan
8000 IU/0.8 ml
7000 IU/0,7 ml
800mg + 100mg once daily
800 mg + 100 mg jedanput na dan
80339 München, Germany
80339 München Njemačka
80339 München, Germany
80339 München, Njemačka
80440 Glisy France
80440 Glisy Francuska
80538 - Munich Germany
80538 - Munich Njemačka
80636 München Germany
80636 München Njemačka
81 Columbia Turnpike Rensselaer, New York 12144 USA
81 Columbia Turnpike Rensselaer, New York 12144 SAD
81.5% of these patients were on concomitant levodopa therapy.
81,5% bolesnika istodobno je liječeno levodopom .
81.5% of these patients were on concomitant levodopa therapy.
Istodobno liječenje s levodopom zabilježeno je u 81,5% bolesnika.
81227 Yavne Israel
81227 Yavne Izrael
81377 Munich Germany
81377 Munich Njemačka
81379 Munich Germany
81379 Munich Njemačka
82% (299/363)
Premoštavajuća fibroza
82.7)
N/Pc
82.8% to 96.4%
82,8 % do 96,4
8203 AA Lelystad The Netherlands
8203 AA Lelystad Nizozemska
82041 Oberhaching Germany
82041 Oberhaching Njemačka
821 08 Bratislava, SR
IRIS d.o.o.
82166 Graefelfing GERMANY
82166 Graefelfing NJEMAČKA
8221 RA Lelystad The NETHERLANDS
8221 RA Lelystad NIZOZEMSKA
82377 Penzberg GERMANY
82377 Penzberg NJEMAČKA
8243 PZ Lelystad The Netherlands
8243 PZ Lelystad Nizozemska
83% treatment-naïve patients 47% ≥2 relapses in prior year
83% bolesnika koji prethodno nisu bili liječeni 47% ≥2 relapsa u prethodnoj godini
83.3% (80, 87) in the randomised Glivec and the IFN+Ara-C groups, respectively (p=0.073, log-rank test).
87) u randomiziranoj Glivec, odnosno INF+Ara-C skupini (p=0,073, log-rang test).
834
negativna
83607 Holzkirchen Germany
83607 Holzkirchen Njemačka
83714 Miesbach Germany
83714 Miesbach Njemačka
83870 Signes France
Francuska
84 (2 x 42 x 1) capsules (unit dose) (multipack)
84 (2 x 42 x 1) kapsule
84 (2 x 42 x 1) capsules (unit dose) (multipack)
84 (2 x 42 x 1) kapsule (jedinična doza) (višestruko pakiranje)
84 (2 x 42) capsules
84 (2 x 42) kapsule (višestruko
84 (2 x 42) patches (multipack)
84 (2 x 42) flastera (višestruko pakovanje)
84 (2 x 42) sachets (multipack)
84 (2 x 42) vrećice (višestruko pakovanje)
84 (3 wallets of 28) film-coated tablets 98 (7 wallets of 14) film-coated tablets 10x1 film-coated tablet
84 (3 kartonska ovitka s 28) filmom obloženih tableta 98 (7 kartonskih ovitaka s 14) filmom obloženih tableta 10x1 filmom obložena tableta
84 (3 x 28) film-coated tablets
84 (3 x 28) filmom obloženih tableta
84 (3 x 28) tablets (multipack)
84 (3 x 28) tableta (višestruko pakiranje)
84 (3 x 28) tablets (multipack)
84 (3 x 28) tableta (višestruko pakovanje)
84 capsules
84 kapsula
84 capsules (4 blister cards of 21 x 20 mg) (60 mg/day dose for a 28 day supply)
84 kapsule (4 blister kartice od 21 x 20 mg) (dnevna doza od 60 mg za primjenu tijekom 28 dana)
84 capsules (4 blister cards of 21 x 20 mg) (60 mg/day dose)
84 kapsule (4 blister kartice od 21 x 20 mg) (60 mg/dnevna doza)
84 cases of confusional state/disorientation have been reported cumulatively.
Kumulativno je prijavljeno 84 slučajeva konfuznog stanja/dezorijentacije.
84 film-coated tablets
Za primjenu kroz usta
84 film-coated tablets (calendar blister)
84 filmom obloženih tablet (kalendarski blister)
84 film-coated tablets.
84 filmom obloženih tableta.
84 hard capsules
84 kapsule
84 hard capsules
84 tvrdih kapsula
84 mg (0.85 ml) twice daily
84 mg (0,85 ml) dva puta na dan
84 mg of maltose per tablet
84 mg na maltozu po tableti
84 patches
84 flastera
84 prolonged-release tablets
84 tablete s produljenim oslobađanjem
84 single-use vials
84 bočice za jednokratnu upotrebu
84 tablets
84 tableta
84 tablets
EU/1/09/566/005
84 tablets: EU/1/08/480/005
84 tablete: EU/1/08/480/005
84 tablets: EU/1/08/480/011
84 tablete: EU/1/08/480/011
84 tablets: EU/1/08/480/017
84 tableta: EU/1/08/480/017
84 tablets: EU/1/08/480/017
84 tablete: EU/1/08/480/017
84 tablets: EU/1/10/632/005
84 tableta: EU/1/10/632/005
84 tablets: EU/1/10/632/005
84 tablete: EU/1/10/632/005
84 tablets: EU/1/10/632/012
84 tableta: EU/1/10/632/012
84 tablets: EU/1/10/632/019
84 tableta: EU/1/10/632/019
84 tablets: four transparent calendar blisters of 21 tablets each.
84 tablete: četiri prozirna kalendarska blistera, svaki s 21 tabletom.
84 x 1 capsules (unit
84 x 1 kapsula
84 x 1 capsules (unit
84 x 1 kapsula (jedinična doza)
84 x 1 capsules (unit dose)
84 x 1 kapsula (jedinična doza)
84 x 1 film-coated tablets
84 x 1 filmom obložena tableta
84 x 1 film-coated tablets
84 x 1 filmom obložene tablete
84 x 1 hard capsules
84 x 1 tvrda kapsula
84 x 1 tablet (unit dose)
84 x 1 tableta (jedinična doza)
84 x1 capsules (unit dose)
84 x1 kapsula (jedinična doza)
84% (122/145)
(84%, 94%)b
84,496 subjects, 65 years and older received a single vaccination of either Prevenar 13 or placebo in a 1:1 randomization.
84 496 ispitanika u dobi od 65 i više godina dobilo je jednokratnu dozu cjepiva Prevenar 13 ili placeba u randomizaciji 1:1.
84.0 % of patients receiving ibandronic acid 2.5 mg daily.
2,5 mg jedanput dnevno.
84.0 micrograms
84,0 mikrograma
84.11 (11.073)
Medijan (minimum - maksimum)
84.3 (72.9 to 95.1)
84,3 (72,9 do 95,1)
847/2000 as further explained in the European Public Assessment Report.
847/2000, a što je dodatno objašnjeno u Europskom javnom izvješću o ocjeni lijeka.
8487
tipa 16/18
84x1 film-coated tablets
84x1 filmom obloženih tableta
84x1 film-coated tablets
90x1 filmom obloženih tableta
85 hours
85 sati
85 mcg /
Al)
85 mg once daily
85 mg jedanput na dan
85 mg/m2 intravenous
85 mg/m2 intravenski
85 mg/m2 intravenous
85 mg/m2 intravenski/2
85 mg/m2 intravenous 2 hr
85 mg/m2 intravenski 2 sata
85 mg/m2 IV 2 hr
85 mg/m2 i.v./2 sata
85 to 90% of the maximal blood- pressure-lowering effect was observed after 2 weeks.
85 do 90% maksimalnog učinka sniženja krvnoga tlaka opaženo je nakon 2 tjedna.
85.1 months
85,1 mjesec
85.3% to 97.8%
85,3 % do 97,8
85.8
dasabuvira
850 mg single dose
jedna doza od 850 mg
852 mg cefovecin (as sodium salt)
852 mg cefovecina (kao natrijeve soli)
85716 Unterschleissheim GERMANY
85716 Unterschleissheim Njemačka
86 (81, 90)
Svi bolesnici† 86 (81, 90)
86 p<0.0001
86 p<0,0001
86.7% (p=0.015)*
86,7% (p = 0,015)
86077 Pozzilli (IS) Italy
86077 Pozzilli (IS) Italija
865 patients with leukaemia treated with dasatinib in Phase II clinical studies, the mean changes from baseline in QTc interval using Fridericia's method (QTcF) were 4 - 6 msec; the upper 95% confidence intervals for all mean changes from baseline were < 7 msec (see section 4.8).
U 865 bolesnika s leukemijom koji su bili liječeni dasatinibom u kliničkim ispitivanjima faze II, prosječne promjene od početnih vrijednosti QTc intervala prema Fridericija metodi (QTcF) iznosile su 4-6 msek; gornje granice 95% intervala pouzdanosti za sve prosječne promjene u odnosu na početne vrijednosti bile su <7 msek (vidjeti dio 4.8).
87 mg dinotefuran,
87 mg dinotefurana,
87 to 137
87 do 137
87% [65,95]
parova (SAD)
87% of animals challenged with virus heterologous to the vaccine strain after 2 doses of vaccine were protected, and a single dose of heterologous vaccine protected 56% of the animals.
87% životinja zaraženih virusom koji je heterologan soju cjepiva bilo je zaštićeno nakon 2 doze cjepiva, dok je jedna doza heterolognog cjepiva zaštitila 56% životinja.
87% of animals challenged with virus heterologous to the vaccine strain after 2 doses of vaccine were protected, and a single dose of heterologous vaccine protected 56% of the animals.
87% životinja zaraženih virusom koji je heterologan soju cjepiva bilo je zaštićeno nakon 2 doze cjepiva, dok je samo jedna doza heterolognog cjepiva zaštitila 56% životinja.
87% of patients enrolled had an ECOG performance status score of 0-1.
87% uključenih bolesnika imalo je opće stanje prema ECOG-u 0-1.
87b [84, 107]
[84, 107]
88 single-use 1 ml ampoules of solvent
88 ampula s otapalom volumena 1 ml za jednokratnu upotrebu
88 single-use 1 ml ampoules of solvent This pack is not to be sold separately.
88 ampula s otapalom volumena 1 ml za jednokratnu upotrebu Ovo pakiranje ne smije se prodavati zasebno.
88.4% (p=0.002)*
88,4% (p = 0,002)
88.6-96.4%) in the nilotinib 300 mg twice daily group, 92.2% (95% CI: 88.5-95.9%) in the nilotinib 400 mg twice daily group and 88.0% (95% CI: 83.0-93.1%) in the imatinib 400 mg once daily group.
88,5-95,9%) u skupini koja je primala 400 mg nilotiniba dva puta na dan te 88,0% (95% CI: 83,0-93,1%) u skupini koja je primala 400 mg imatiniba jedanput na dan.
88.6-96.4%) in the nilotinib 300 mg twice daily group, 92.2% (95% CI: 88.5-95.9%) in the nilotinib 400 mg twice daily group and 88.0% (95% CI: 84.2-94.0%) in the imatinib 400 mg once daily group.
88,5-95,9%) u skupini koja je primala 400 mg nilotiniba dva puta na dan te 88,0% (95% CI: 83,0-93,1%) u skupini koja je primala 400 mg imatiniba jedanput na dan.
88.9)
IP)
88397 Biberach Germany
88397 Biberach Njemačka
89, rue de l'Institut B-1330 Rixensart Belgium
89, rue de l'Institut B-1330 Rixensart Belgija
89100 Sens France
89100 Sens Francuska
89143 Blaubeuren Germany
89143 Blaubeuren Njemačka
89143 Blaubeuren, Germany
89143 Blaubeuren, Njemačka
89143 Blaubeuren-Weiler Germany
89143 Blaubeuren-Weiler Njemačka
893 River Road Conshohocken, PA 19428
GlaxoSmithKline LLC 893 River Road Conshohocken,
8950 Esplugues de Llobregat Barcelona
Angel Guimera 179-181
9 (10.7)
9 (10,7)d [ 5,02; 19,37]
9 (10.7)d [5.02, 19.37]
9 (10,7)d [ 5,02; 19,37]
9 Adverse event identified from clinical trials in the Olanzapine Integrated Database.
9 Nuspojava je identificirana iz kliničkih ispitivanja u integriranoj bazi podataka za olanzapin.
9 Adverse event identified from clinical trials in the Olanzapine Integrated Database.
Djelotvornost olanzapina nije utvrđena u ovim ispitivanjima.
9 cartridges
8 uložaka
9 cartridges
9 uložaka
9 cartridges of 3ml.
9 uložaka od 3 ml.
9 Estimated frequency based on all clinical trial data.
9 Učestalost procijenjena na temelju svih podataka iz kliničkih ispitivanja.
9 hours after application
9 sati nakon primjene
9 In active comparator controlled trials mean weight increase with pioglitazone given as monotherapy was 2 – 3 kg over one year.
9 U ispitivanjima kontroliranima aktivnim komparatorom, prosječno povećanje tjelesne težine uz monoterapiju pioglitazonom iznosilo je 2-3 kg tijekom jedne godine.
9 In clinical trials with pioglitazone the incidence of elevations of ALT greater than three times the upper limit of normal was equal to placebo but less than that seen in metformin or sulphonylurea comparator groups.
9 U kliničkim ispitivanjima pioglitazona, incidencija povišenja ALT-a više od tri puta iznad gornje granice normale bilo je jednako često kao uz placebo, ali manje često nego u skupinama koje su kao komparator primale metformin ili sulfonilureju.
9 mcg/day
9 µg/dan
9 mcg/day via continuous infusion
9 µg/dnevno putem kontinuirane infuzije
9 mg/kg once every 24 hours
9 mg/kg jedanput svaka 24 sata
9 mg/kg once every 24 hours infused over 60 minutes
9 mg/kg jedanput svaka 24 sata infuzijom tijekom 60 minuta
9 mg/kg twice a day (a maximum dose of 350 mg twice daily)
9 mg/kg dvaput na dan (najviša doza je 350 mg dvaput na dan)
9 mg/ml (0.9%) solution for infusion.
5%-tna otopina glukoze ili otopina za infuziju natrijevog klorida 9 mg/ml (0,9%)
9 mg/ml (0.9%) solution for infusion.
9 mg/ml (0,9%)
9 ml Telzir oral suspension) twice daily with 100 mg ritonavir once daily.
9 ml Telzir oralne suspenzije) 2 puta dnevno sa 100 mg ritonavira jedanput dnevno.
9 patients responded after receiving the initial induction dose, 16 patients responded by week 10.
Devet bolesnika odgovorilo je nakon primanja početne indukcijske doze, a 16 bolesnika odgovorilo je do 10. tjedna.
9 pens of 3 ml.
9 brizgalica od 3 ml.
9 pre-filled pens
brizgalica
9 pre-filled pens
EU/1/97/030/194